The Lancet 2026: PCOS Is Now PMOS—What This Means for Women’s Health

On May 12, 2026, The Lancet published a landmark health policy paper announcing the official renaming of a condition that affects more than 170 million women worldwide, formerly known as Polycystic Ovary Syndrome (PCOS) , now to be called Polyendocrine Metabolic Ovarian Syndrome (PMOS) .

The name change follows a 14-year global consensus process involving 56 leading academic, clinical and patient organizations and more than 22,000 survey responses from patients and health professionals across all world regions.

The authors stated that the old name was “inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma.” Up to 70% of affected individuals remain undiagnosed today.

Why “PMOS”? A New Name Reframes Women’s Health

The new name, Polyendocrine Metabolic Ovarian Syndrome (PMOS), is built on three deliberately chosen components, each carrying critical clinical meaning:

1. Polyendocrine encompasses core symptoms such as hyperandrogenism, neuroendocrine dysregulation and disturbed gonadotropin signaling; acknowledging that PMOS is not an isolated ovarian issue but a multi-hormone systemic condition.

2. Metabolic makes explicit what evidence has long supported: insulin resistance is present in roughly 85% of patients overall and 75% of lean patients.

This reframe pushes cardiovascular risk, type 2 diabetes, fatty liver and hypertension into routine care, not afterthoughts.

3. Ovarian is retained to preserve continuity and acknowledge follicular and ovulatory dysfunction, without implying that cysts are central.

For women in general, this renaming encourages earlier screening for metabolic disturbances, better integration of endocrine care, and reduced stigma around a condition long misunderstood as purely a fertility problem.

What this means for women pursuing IVF

As PMOS is one of the most common factors causing anovulatory infertility, the renaming carries direct implications for those pursuing fertility treatment

A fertility specialist quoted in The Lancet coverage explained: “Recognizing PMOS as a ‘polyendocrine’ condition acknowledges that infertility is driven by multiple interacting hormonal disturbances, including insulin and neuroendocrine hormones, rather than just an isolated ovarian disorder. This opens doors for treatments that target the underlying metabolic causes, such as managing insulin resistance, to restore spontaneous ovulation and improve pregnancy outcomes.” 

In practical terms, women seeking IVF can expect:

1. A diagnostic process that looks beyond ovarian morphology to include comprehensive metabolic and endocrine evaluation.

2. Treatment protocols that integrate insulin sensitization and lifestyle intervention as part of the preparation for embryo transfer.

3. A more holistic, less stigmatizing clinical conversation, moving away from a “cyst-centric” framing toward systemic care.

The road ahead

A three-year transition period is now underway, with the new name to be fully implemented in the 2028 International Guideline update.

At this stage, educational and popular science work will be fully launched, covering medical professionals, patient groups and even the general public.

Meanwhile, international experts are also actively communicating with the WHO to promote the formal inclusion of this name in the International Classification of Diseases (ICD) system.

Sources: The Lancet (May 12, 2026), Monash University / International PCOS Network, Society for Endocrinology, AJMC, Medical News Today.

—At CEF, we believe fertility care must be grounded in accurate biology and patient-centered communication.

This renaming is not just a linguistic update. It is a validation that conditions affecting fertility are endocrine metabolic at their core, and that effective IVF support begins with understanding the whole system.

Thinking about how PMOS applies to your personal fertility plan? We are happy to answer your questions, with no pressure, just evidence-based guidance.